TY  - GEN
AU  - Di Bartolomeo,M
AU  - Pietrantonio,F
AU  - Perrone,F
AU  - Dotti,K F
AU  - Lampis,A
AU  - Bertan,C
AU  - Beretta,E
AU  - Rimassa,L
AU  - Carbone,C
AU  - Biondani,P
AU  - Passalacqua,R
AU  - Pilotti,S
AU  - Bajetta,E
TI  - Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT
SN  - 1776-260X
PY  - 2015///0207
KW  - Adenocarcinoma
KW  - drug therapy
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal, Humanized
KW  - administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Biomarkers, Tumor
KW  - genetics
KW  - Cetuximab
KW  - Colorectal Neoplasms
KW  - DNA Mutational Analysis
KW  - Disease-Free Survival
KW  - Drug Resistance, Neoplasm
KW  - Female
KW  - GTP Phosphohydrolases
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Male
KW  - Membrane Proteins
KW  - Mutation
KW  - Nuclear Proteins
KW  - Organoplatinum Compounds
KW  - Oxaliplatin
KW  - Proto-Oncogene Proteins
KW  - Proto-Oncogene Proteins B-raf
KW  - Proto-Oncogene Proteins p21(ras)
KW  - Reverse Transcriptase Polymerase Chain Reaction
KW  - Tegafur
KW  - Transcription Factors
KW  - Tumor Suppressor Protein p53
KW  - Uracil
KW  - ras Proteins
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study
UR  - https://doi.org/10.1007/s11523-013-0283-8
ER  -